Mesenchymal stem cells in solid organ transplantation (MiSOT) fourth meeting: Lessons learned from first clinical trials

Transplantation

Volumn 96, Issue 3, 2013, Pages 234-238

  Franquesa, Marcella ^a   Hoogduijn, Martin J ^a   Reinders, Marlies E ^b   Eggenhofer, Elke ^c   Engela, Anja U ^a   Mensah, Fane K ^a   Torras, Joan ^d   Pileggi, Antonello ^e   Van Kooten, Cees ^b   Mahon, Bernard ^f   Detry, Oliver ^g   Popp, Felix C ^c   Benseler, Volker ^c   Casiraghi, Federica ^h   Johnson, Christian ^c   Ancans, Janis ⁱ   Fillenberg, Barbara ^c   Delarosa, Olga ^j   Aran, Josep M ^k   Roemeling Vanrhijn, Marieke ^a   Pinxteren, Jef ^l   Perico, Norberto ^h   Gotti, Eliana ^m   Christ, Bruno ⁿ   Reading, James ^o   Introna, Martino ^m   Deans, Robert ^p   Shagidulin, Murat ^q   Farré, Ramon ^r   Rambaldi, Alessandro ^m   Sanchez Fueyo, Albert ^o   Obermajer, Natasha ^c   Pulin, Andrey ^q   Dor, Frank J M F ^a   Portero Sanchez, Isabel ^s   Baan, Carla C ^a   Rabelink, Ton J ^b   Remuzzi, Giuseppe ^h   Betjes, Michiel G H ^a   Dahlke, Marc H ^c   Grinyó, Josep M ^d   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e Diabetes Research Institute   (United States)

^f NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

ⁱ UNIVERSITY OF LATVIA   (Latvia)

^j TiGenix   (Spain)

^k HOSPITAL DURAN I REYNALS   (Spain)

^l ReGenesys   (Belgium)

^m PAPA GIOVANNI XXIII HOSPITAL   (Italy)

ⁿ UNIVERSITY OF LEIPZIG   (Germany)

^o KING'S COLLEGE LONDON   (United Kingdom)

^p ATHERSYS INC   (United States)

^q I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^r INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^s UNIVERSIDAD FRANCISCO DE VITORIA   (Spain)

more..

Author keywords

Immunomodulation; Mesenchymal stem cells; Position paper; Transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

CELL DIFFERENTIATION; CELL EXPANSION; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; EXPERIMENTAL STUDY; GOVERNMENT REGULATION; HEALTH CARE POLICY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MEDICAL RESEARCH; MESENCHYMAL STEM CELL TRANSPLANTATION; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT;

CLINICAL TRIALS AS TOPIC; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION;

EID: 84881612444     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318298f9fa     Document Type: Review

References (19)

1. Dahlke MH, Hoogduijn M, Eggenhofer E, et al. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 2009; 88: 614.
2. Hoogduijn MJ, Popp FC, Grohnert A, et al. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010; 90: 124.
3. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6: 412.
4. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307: 1169.
5. Reinders ME, de Fijter JW, Roelofs H, et al. Autologous bone marrowderived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2013; 2: 107.
6. Detry O. Mesenchymal stem cells after renal or liver transplantation. ClinicalTrials.gov Identifier: NCT01429038, September 1, 2011.
7. Remuzzi G. Mesenchymal stem cells under basiliximab/low dose RATG to induce renal transplant tolerance. ClinicalTrials.gov Identifier: NCT00752479, July 23, 2008.
8. Popp FC, Fillenberg B, Eggenhofer E, et al. Safety and feasibility of thirdparty multipotent adult progenitor cells for immunomodulation therapy after liver transplantationVa phase I study (MISOT-I). J TranslMed 2011; 9: 124.
9. Hoogduijn MJ, Crop MJ, Korevaar SS, et al. Susceptibility of human mesenchymal stem cells to tacrolimus,mycophenolic acid, and rapamycin. Transplantation 2008; 86: 1283.
10. Eggenhofer E, Renner P, Soeder Y, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 2011; 25: 141.
11. Roemeling-van Rhijn M, Reinders ME, de Klein A, et al.Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney Int 2012; 82: 748.
12. Reinders ME, Roemeling-van Rhijn M, Khairoun M, et al. Bone marrow-derived mesenchymal stromal cells from patients with endstage renal disease are suitable for autologous therapy. Cytotherapy 2013; 15: 663.
13. Peng Y, Ke M, Xu L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 2013; 95: 161.
14. Casiraghi F, Remuzzi G, Abbate M, et al. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev 2012; 9: 65.
15. Torsvik A, Rosland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects crosscontamination: putting the research field on track [letter]. Cancer Res 2010; 70: 6393.
16. Vogel G. Cell biology. To scientists' dismay, mixed-up cell lines strike again. Science 2010; 329: 1004.
17. Ancans J. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Front Immunol 2012; 3: 253.
18. Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297.
19. Dazzi F, Lopes L, Weng L. Mesenchymal stromal cells: a key player in 'innate tolerance' Immunology 2012; 137: 206.